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Nosocomial infection caused byAcinetobacter baumannii is of great concern due to its increasing resistance tomost antimicrobials.
In this study, 54 nonrepeat isolates of A. baumannii from the main tertiary hospital in Terengganu, Malaysia, were analyzed for
their antibiograms and genotypes. Out of the 54 isolates, 39 (72.2%) were multidrug resistant (MDR) and resistant to carbapenems
whereas 14 (25.9%) were categorized as extensive drug resistant (XDR) with additional resistance to polymyxin B, the drug of “last
resort.” Pulsed-field gel electrophoresis analyses showed that the polymyxin-resistant isolates were genetically diverse while the
carbapenem-resistant isolates were clonally related. The 14 XDR isolates were further investigated for mutations in genes known
to mediate polymyxin resistance, namely, pmrCAB, and the lipopolysaccharide biosynthesis genes, lpxA, lpxC, lpxD, and lpsB. All
14 isolates had a P102H mutation in pmrA with no mutation detected in pmrC and pmrB. No mutation was detected in lpxA but
each polymyxin-resistant isolate had 2–4 amino acid substitutions in lpxD and 1-2 substitutions in lpxC. Eight resistant isolates also
displayed a unique H181Y mutation in lpsB. The extent of polymyxin resistance is of concern and the novel mutations discovered
here warrant further investigations.
1. Introduction
Acinetobacter baumannii is a Gram-negative bacterium
increas-ing-ly found in the hospital environment due to its
ability to survive for long periods on inanimate objects [1,
2]. Nosocomial A. baumannii isolates are mostly multidrug
resistant (MDR) (i.e., resistant towards more than three
classes of antibiotics) [3]. However, extensive drug resistant
(XDR) isolates, which are resistant to all but one or two classes
of antibiotics, and even pandrug resistant (PDR) isolates
that are resistant to all classes of antibiotics, are developing
at an alarming rate [4]. Since A. baumannii has the ability
to colonize both viable and damaged tissues and is also
resistant towards nearly all antimicrobials, it has become a
cause of great concern. Carbapenems are among the very
few antibiotics left that can be used for the treatment of A.
baumannii infections. Nevertheless, the efficacy of carbapen-
ems is increasingly compromised by the rapid emergence
of carbapenem-hydrolysing 𝛽-lactamase enzymes. Several
types of class D 𝛽-lactamases including OXA-23, OXA-24,
OXA-58, and intrinsic OXA-51-like enzymes are known to be
important contributors to carbapenem resistance [5].
The rapid development of carbapenem-resistant MDR A.
baumannii has led to the use of polymyxins (in particular
polymyxin B and colistin or polymyxin E) as the drug of
“last resort” [6]. Polymyxins are cyclic, positively charged
peptide antibiotics capable of posing antimicrobial activities
to a broad variety of Gram-negative pathogens, including A.
baumannii, due to their interaction with the lipid A moiety
of lipopolysaccharide (LPS).This leads to the disorganization
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and disruption of the outer membrane integrity, causing
cytoplasmic leakage [7]. Unfortunately, the intensive use of
the polymyxins in recent years has led to the emergence
of polymyxin heteroresistant and resistant A. baumannii, as
high as 40.7% reported in Spain [8] and 30.6% in Korea [9].
The basis of polymyxin resistance in A. baumannii has
only recently been investigated and several mechanisms have
been proposed. Several genetic loci have been implicated in
the resistance towards polymyxins in Acinetobacter, namely,
the pmrCAB operon [10, 11] and the lpxA, lpxC, lpxD [12,
13], and lpsB genes, that are involved in LPS biosynthesis
[14]. Resistance can arise through mutations in the two-
component system PmrAB, in which the downstream target
PmrC catalyzes the addition of phosphoethanolamine to the
lipid A component of LPS [10, 11, 15]. This modification
reduces the net negative charge of the outer membrane thus
reducing the affinity of polymyxins for the target. Park et al.
(2011) [16] also showed that increased expression of pmrAB
could be essential for colistin resistance in A. baumannii.
Mutations or insertions in the genes encoding the lipid A
biosynthesis machinery, namely, the lpxA, lpxC, or lpxD
genes, also mediate polymyxin resistance by abolishing the
production of LPS, thereby eliminating the target of polymyx-
ins [12, 13, 17]. Hood et al. (2013) [14] recently reported the
identification of over 20 genes that are implicated in inducible
colistin tolerance in A. baumannii, with majority of the
genes involved in processes that protect the bacterium from
osmotic stress. One of the genes identified, lpsB, encodes a
glycosyltransferase involved in LPS biosynthesis. Polymyxin
resistance in A. baumannii thus developed through intrinsic
mechanisms that respond and adapt to polymyxin treatment
and not through acquisition of horizontally transferred resis-
tance genes [12, 13].
To our knowledge, there has been no published data on
polymyxin-resistant isolates of A. baumannii from Malaysia.
In this study, we determined the resistance profiles of A.
baumannii isolated from Hospital Sultanah Nur Zahirah
(HSNZ), the main tertiary hospital located in the state of
Terengganu in the east coast of Peninsular Malaysia. The
genetic diversity of theA. baumannii isolates was determined
by pulsed-field gel electrophoresis (PFGE). This study also
aims to determine the presence and distribution of genes
encoding the class D carbapenemase 𝑏𝑙𝑎OXA-51, 𝑏𝑙𝑎OXA-23,
𝑏𝑙𝑎OXA-24, and 𝑏𝑙𝑎OXA-58, as well as the class B carbapenemase
(or metallo-𝛽-lactamase) genes 𝑏𝑙𝑎VIM and 𝑏𝑙𝑎IMP in the
clinical isolates of A. baumannii. Besides that, we also aim
to investigate the type of mutations that occur within the
pmrCAB, lpxA, lpxC, lpxD, and lpsB genes that may confer
resistance to polymyxin. Findings from this research project
will help to determine the antimicrobial resistance, distribu-
tion of carbapenem and polymyxin resistance determinants,
and the clonality of the A. baumannii isolates from HSNZ,
thereby providing valuable information regarding this impor-
tant nosocomial pathogen in this region.
2. Materials and Methods
2.1. Bacterial Isolates: Identification and Genotyping. Fifty-
four nonrepeat clinical isolates of A. baumannii were
collected throughout 2011 from sporadic cases of infection in
Hospital Sultanah Nur Zahirah (HSNZ). The isolates were
isolated and initially identified by standard biochemical
methods at the clinical microbiology laboratory. Single
colonies of A. baumannii were then cultured into nutrient
broth and incubated at 37∘C for 24 hours. Confirmation of
the 54 isolates was done by 16S rDNA amplification and
sequencing. Genomic DNA was extracted from the bacterial
isolates using the Wizard Genomic DNA Purification Kit
(Promega, Madison, WI, USA) and subjected to PCR using
16S rDNA universal primers [18] (Table 1). Strain typing ofA.
baumanniiwas carried out by pulsed-field gel electrophoresis
(PFGE), as previously described [19]. Briefly, chromosomal
DNA for PFGE analysis was prepared in agarose gel blocks,
digestedwith restriction endonucleaseApaI (Promega,Madi-
son, WI, USA). Restriction fragments were separated by
using the CHEF Mapper (Bio-Rad, Hercules, CA, USA)
with 0.5 × TBE buffer for 26 h at 14∘C with pulse times of
2–40 s. XbaI-digested Salmonella enterica ser. Braenderup
H9812 was used as the molecular size standard. The PFGE
profiles were analyzed using BioNumerics version 6.0 soft-
ware (Applied Maths, Kortrijk, Belgium). The unweighted
pair group method with averages (UPGMA), with a position
tolerance for comparison of 1.5%, was used to produce the
dendrogram.
2.2. Antimicrobial Susceptibility: MIC Determination for Car-
bapenems and Polymyxin B. The Kirby-Bauer disc diffusion
method was used to test the susceptibility of the A. bau-
mannii isolates to the following 12 antibiotics (Oxoid Ltd.,
Basingstoke, UK): gentamicin (10 𝜇g), tobramycin (10 𝜇g),
amikacin (30 𝜇g), ciprofloxacin (5𝜇g), levofloxacin (5𝜇g),
piperacillin-tazobactam (100/10 𝜇g), cefotaxime (30 𝜇g), cef-
tazidime (30 𝜇g), cefepime (30 𝜇g), ampicillin-sulbactam
(10/10 𝜇g), tetracycline (30 𝜇g), and doxycycline (30 𝜇g). The
antibiotic susceptibility test was carried out on Mueller
Hinton (Hi media) Agar swabbed with 0.5 McFarland stan-
dard suspension of A. baumannii and incubated at 37∘C for
24 h. Guidelines from the Clinical and Laboratory Standard
Institute (CLSI) [20] were used to interpret the diameters of
the inhibition zones produced.
Bacterial cultures of A. baumannii adjusted to 0.5 McFar-
land standard were used to determine theminimal inhibitory
concentration (MIC) to imipenem and meropenem using
M.I.C. Evaluator (M.I.C.E.) strips (Oxoid Ltd., Basingstoke,
UK). Inoculated media were incubated at 35 ± 2∘C for 16–
20 h.TheMIC values of the respective inhibition ellipses that
interact with the strips were taken and recorded. Data were
analyzed according to the guidelines given for M.I.C.E. strips
and the MIC was determined.
MIC values for polymyxin B were determined by the
agar dilutionmethod [21]. Agar dilution plates were prepared
by using Mueller-Hinton Agar added with concentrations
of 2, 4, 8, 16, 32, 64, and 128 𝜇g/mL polymyxin B sulfate
(Sigma-Aldrich, St. Louis, MO, USA). A multipoint inoc-
ulator was used to deliver bacterial suspensions adjusted
to 0.5 McFarland standard onto the agar surface and the
agar subsequently incubated at 35 ± 2∘C for 16–20 h. The
MIC value for polymyxin B was determined as the lowest
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concentration of the antibiotic in which the bacteria were
susceptible.The standard breakpoint for resistance according
to the CLSI guideline [20] was ≥ 4 𝜇g/mL.
2.3. Detection of Carbapenem- and Polymyxin-Resistant
Determinants, DNA Sequencing, and Sequence Analysis. The
PCR primers and conditions used to detect the presence
of several carbapenem resistance genes such as 𝑏𝑙𝑎OXA-23,
𝑏𝑙𝑎OXA-51, 𝑏𝑙𝑎OXA-24, 𝑏𝑙𝑎OXA-58, 𝑏𝑙𝑎IMP, and 𝑏𝑙𝑎VIM are indi-
cated in Table 1.The validity of the ampliconswas determined
by DNA sequencing. Briefly, the amplified products were
purified by using the Wizard SV Gel and PCR Clean-Up
System (Promega, Madison, WI, USA) and then submitted
to a commercial facility (First Base Sdn. Bhd., Malaysia) for
sequencing.
Genetic determinants that have been implicated in con-
ferring polymyxin resistance in A. baumannii, namely, the
pmrCAB, lpxA, lpxC, lpxD, and lpsB genes, were PCR-
amplified using specific primers and conditions as shown in
Table 1. Purified PCR products were then sequenced at the
commercial facility (First Base Sdn. Bhd., Malaysia).
DNA sequences obtainedwere edited using BioEdit v7.0.9
(downloadable from http://www.mbio.ncsu.edu/bioedit/
page2.html) and analyzed with BLAST at the National Center
of Biotechnology Information website (http://www.ncbi.nlm
.nih.gov/BLAST). Sequence analysis was also done by using
ExPASy translate tool at the Swiss Institute of Bioinforma-
tics website (http://web.expasy.org/translate/) and ClustalW2
multiple sequence alignment program (http://www.ebi.ac
.uk/Tools/msa/clustalw2/).
3. Results
3.1. Antibiotic Susceptibility Profiles of A. baumannii . DNA
sequence analyses of the 16S rRNA amplicons showed ≥99%
sequence identity withA. baumannii 16S rRNA genes validat-
ing that all 54 isolates used in this study were A. baumannii.
High percentages of antibiotic resistance were observed
for the following antibiotics: tetracycline (87%), piperacillin-
tazobactam (72.2%), cefotaxime (72.2%), ceftazidime
(72.2%), cefepime (72.2%), levofloxacin (70.4%), ampicillin-
sulbactam (68.5%), gentamicin (66.7%), ciprofloxacin
(66.7%), tobramycin (64.8%), doxycycline (61.1%), and ami-
kacin (57.4%). The isolates also showed high resistance for
carbapenems with 77.8% of the isolates resistant to mero-
penem and 74.1% resistant to imipenem. The majority of
the carbapenem-resistant isolates showed MIC values of
> 32 𝜇g/mL. Of the 54 isolates, 39 (or 72.2%) could be
categorized as multidrug resistant (MDR)—that is, resistant
to more than three classes of antibiotics. All MDR isolates
were resistant tomeropenem and imipenem. Polymyxin resi-
stance was assessed by determining the MIC values for
polymyxin B. Of the 54 isolates, 14 (or 25.9%) were cate-
gorized as polymyxin resistant (MIC ≥ 4 𝜇g/mL). Four
of these isolates had MIC values of > 128𝜇g/mL for
polymyxin B. All 14 polymyxin-resistant isolates could also
be categorized as extensive drug resistant (XDR) isolates
based on the criteria proposed by Magiorakos et al. (2012)
[22].
3.2. Detection of Class D and Class B Carbapenemase Genes.
PCR was used to detect the presence of the class D carbapen-
emase genes 𝑏𝑙𝑎OXA-51, 𝑏𝑙𝑎OXA-23, 𝑏𝑙𝑎OXA-24, and 𝑏𝑙𝑎OXA-58.
All 54 A. baumannii isolates yielded 𝑏𝑙𝑎OXA-51 amplicons of
the expected size of 353 bp. Sequence analyses of the ampli-
fied products confirmed their identity as 𝑏𝑙𝑎OXA-51 or
𝑏𝑙𝑎OXA-51-like gene. Forty-one (75.9%) of the 54 isolates yielded
𝑏𝑙𝑎OXA-23 amplicons of the expected size of 501 bp, and
sequencing of the amplified products validated the identity
as 𝑏𝑙𝑎OXA-23. None of the isolates harbor the 𝑏𝑙𝑎OXA-24 or
the 𝑏𝑙𝑎OXA-58 genes. Similarly, no class Bmetallo-𝛽-lactamase
(MBL) genes, 𝑏𝑙𝑎IMP or 𝑏𝑙𝑎VIM, were found in all the isolates
tested.
3.3. Sequence Analyses of Polymyxin Resistance Determinants.
All 14 polymyxin B resistant isolates were each subjected
to PCR amplifications that target the pmrCAB, lpxA, lpxC,
lpxD, and lpsB genes and the resulting amplicons were
sequenced. The three isolates (AC6, AC11, and AC19) that
were susceptible to polymyxin B were used as controls.
In this study, we found as many as 11 different point
mutations within the pmrB gene when compared to the
reference isolates ATCC 17978 and ATCC 19606 but these
mutations were similarly found in the polymyxin-sensitive
isolates. Thus, when the pmrB sequences of 14 polymyxin-
resistant isolates were compared with the 3 polymyxin-
sensitive isolates, no mutations within the pmrB gene could
be found. Similarly, when comparing the sequences of the
response regulator gene pmrA, 3 different point mutations
(R149K, T153I, and Q165P) were observed but these muta-
tions were commonly found in both sensitive and resistant
isolates. However, all 14 resistant isolates had a P102H
mutationwithin pmrA that was absent in the sensitive isolates
(Table 2). When comparing the sequences for the pmrC gene
that encodes lipid A phosphoethanolamine transferase, up
to 8 point mutations were found in comparison with the
reference isolates. However no difference was found amongst
the polymyxin-sensitive and polymyxin-resistant isolates.
The lpxA, lpxC, and lpxD genes encode the first three
enzymes in the lipid A biosynthesis pathway. No mutation
was found in lpxA. In contrast, lpxD showed up to 4 amino
acid mutations in each resistant isolate while lpxC had 1-
2 amino acid mutations (Table 2). The 14 resistant isolates
had the K141R, S158R, or both mutations in lpxC which
encodes the enzyme involved in the second step of the lipid
A biosynthesis pathway. The lpxD gene showed the most
number of mutations variation among the resistant isolates
with a total of 13 different amino acid substitutions. Each
resistant isolate had between 2 and 4 amino acid substitutions
in lpxD and most of the mutations occurred between amino
acid residues 150 and 190 of LpxD. Further comparison of
the lpxD sequence was carried out with known polymyxin-
sensitive isolates in the database and results of the multiple
sequence alignment (data not shown) indicated that the
amino acid substitutions found in our resistant isolates are
unique.
The lpsB gene encodes a glycosyltransferase involved in
the biosynthesis of the LPS core and was recently implicated
in A. baumannii colistin resistance [14]. Comparison of lpsB
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Table 2: Mutational points found in the polymyxin-resistant determinants among the 14 polymyxin-resistant A. baumannii isolates as
compared to susceptible isolates.
Isolate Mutations
pmrA lpxD lpxC lpsB
AC12 P102H S102T, V141I, and R173G K141R H181Y
AC30 P102H S102T, V141I, and R173G K141R H181Y
AC3 P102H T104K, I178V S158R —
AC13 P102H T121A, N151D, and G169S S158R —
AC16 P102H E50D, V141I K141R H181Y
AC17 P102H E50D, V141I K141R H181Y
AC18 P102H E50D, V141I K141R H181Y
AC20 P102H T15A, T121A, N151D, and G186S K141R, S158R H181Y
AC21 P102H T15A, T121A, N151D, and G186S K141R, S158R —
AC22 P102H E50D, S102T, and I178V K141R, S158R H181Y
AC27 P102H S102T, G169S, and R173G S158R H181Y
AC38 P102H S102T, G169S, I178V, and G186S, K141R —
AC51 P102H E50D, R173G K141R, S158R —
AC61 P102H I178V, S181N K141R, S158R —
∗
Note: no mutation was detected in pmrC, pmrB, and lpxA.
sequences among the 14 resistant isolates, the 3 sensitive
isolates, and the 2 ATCC reference isolates initially showed
that each resistant isolate contained as many as 4 amino acid
substitutions in lpsB. However, when the lpsB sequence from
other polymyxin-sensitive isolates in the database was taken
into account, the majority of these amino acid substitutions
were found to be common among the other polymyxin-
sensitive isolates. The only unique mutation was H181Y and
this substitution was found in 8 of the 14 resistant isolates
(Table 2). The remaining 6 resistant isolates did not harbor
any unique mutation within lpsB.
3.4. Genotyping of Acinetobacter baumannii Isolates by
Pulsed-Field Gel Electrophoresis. PFGE analysis of the 54
ApaI-digested A. baumannii gave 15 reproducible profiles
(pulsotypes) with a Dice coefficient, F, ranging from 0.90 to
1.00. Cluster analysis of the ApaI pulsotypes grouped the 54
A. baumannii isolates into 9 clusters with a cutoff point at
80% similarity (Figure 1). Carbapenem-resistant isolates were
grouped into four main clusters, A–D, while carbapenem-
susceptible isolates were grouped into two clusters,
E and F.
Cluster A is the largest cluster with 21 carbapenem-
resistant isolateswhichwere closely related (81.6% similarity),
with 4 band differences at most (F value = 0.90–1.00). Four
of the isolates within the A cluster were also polymyxin
resistant and XDR. In addition, all the carbapenem-resistant
isolates in clusters A–D were all positive for 𝑏𝑙𝑎OXA-51-like and
𝑏𝑙𝑎OXA-23, whereas the susceptible isolates in clusters E and F
were negative for 𝑏𝑙𝑎OXA-23. However, there was no clustering
among pulsotypes of the polymyxin-resistant, XDR isolates.
In fact, isolates with identical PFGE patterns would differ
in their resistance to polymyxin B. For the three isolates in
cluster C which shared identical PFGE patterns, two of these
(AC17 and AC18) were resistant to polymyxin B but the third
isolate, AC19, was polymyxin sensitive. Both AC17 and AC18
shared identical mutations within the polymyxin-resistance
determinants (i.e., E50D and V141I in lpxD, K141R in lpxC,
and H181Y in lpsB). Likewise, AC29 and AC30 within cluster
A shared an identical PFGE pattern but AC29 was sensitive
to polymyxin B whereas AC30 was resistant.
4. Discussions
This study showed that the HSNZ isolates of A. baumannii
were highly resistant to most antibiotics. Out of 54 isolates,
47 (87%) were resistant to tetracycline, which was the highest
resistance among the 12 antibiotics tested. The percentages
of resistance for carbapenems were also high with 77.8% for
meropenem and 74.1% for imipenem. Although the percent-
age of carbapenem resistance was lower when compared to
the rates reported from another medical facility in Kuala
Lumpur (96.5% for imipenem and 98.2% for meropenem
[19]), the finding that more than 50% of the isolates from
HSNZ were carbapenem resistant is certainly a cause for
concern as carbapenems have been the drugs of choice for
Acinetobacter infections for over a decade [23, 24].
The overuse of carbapenems in hospitals to treat Acine-
tobacter infections has led to outbreaks of carbapenem-
resistant A. baumannii [25]. Outbreaks of isolates carrying
genes encoding OXA-type carbapenemase have increasingly
been reported worldwide in recent years [18]. There are
eight subgroups of OXA carbapenemases, amongst which
are the OXA-23-like, OXA-24-like, OXA-51-like, and OXA-
58-like groups [26]. The 𝑏𝑙𝑎OXA-51-like gene was found in
all 54 A. baumannii isolates and this was to be expected
as the gene is naturally occurring in A. baumannii where
it may be overexpressed leading to carbapenem resistance
[23]. Overexpression of 𝑏𝑙𝑎OXA-51 usually occurs due to the
insertion of the ISAba1 insertion sequence upstream of the
gene which provides the strong promoter sequence [23].
Forty-one out of the 54 isolates of A. baumannii in this study
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Figure 1: Dendrogram of the 54 A. baumannii isolates fromHospital Sultanah Nur Zahirah (HSNZ) using unweighted pair group arithmetic
means methods (UPGMA) from ApaI PFGE profiles. The dotted vertical line indicates the cutoff point of 80% similarity. The sources of
isolation for the A. baumannii isolates are as indicated (wound, W; pus, P; endotracheal secretion, ES; skin, S; urine, U; blood, B). The MIC
values for imipenem (IMP), meropenem (MEM), and polymyxin B (PB) for the isolates are shown as are their susceptibility states (resistant,
R; intermediate, I; susceptible, S) according to CLSI (2012) [20]. PCR detection results for 𝑏𝑙𝑎OXA-23 are also indicated (“+” for present; “−”
for absent). The different clusters at 80% similarity are arbitrarily designated (A)–(E).
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were positive for the 𝑏𝑙𝑎OXA-23 gene. Of these 41 isolates, 37
were resistant to both meropenem and imipenem.
The second and third subgroups of carbapenemhydrolyz-
ing 𝛽-lactamases were the OXA-24-like enzymes and OXA-
58-like enzymes [23] encoded by 𝑏𝑙𝑎OXA-24 and 𝑏𝑙𝑎OXA-58
genes, respectively. In this study, none of the 54 isolates were
found to harbor the 𝑏𝑙𝑎OXA-24 and 𝑏𝑙𝑎OXA-58 genes, similar
to recent findings from Thailand [27]. Likewise, none of
the isolates carried the metallo-𝛽-lactamase genes, 𝑏𝑙𝑎IMP
and 𝑏𝑙𝑎VIM, both of which have not been reported in A.
baumannii in this region. However, reports from Korea
[28, 29] showed that these two genes were implicated in
carbapenem resistance.
The recent emergence of polymyxin-resistant and het-
eroresistant A. baumannii [6] has necessitated the need to
understand themechanism of the development of polymyxin
resistance in this pathogen. Since this older drug has recently
returned in use and has been noted as the drug of last resort
forAcinetobacter infections [6], we investigated the antibiotic
resistance of the HSNZ isolates towards polymyxin B. It was
found that 14 of the 54 isolates (or 25.9%) were resistant
to polymyxin B, of which 4 had MIC values for polymyxin
B >128𝜇g/mL. The mechanism for polymyxin resistance in
A. baumannii has only recently been investigated and the
mainmechanism appeared to be either covalentmodification
of the lipid A portion of LPS [11, 15] or disruption of LPS
biosynthesis [13, 16]. By modification and/or mutations in
the amino acid sequences, negative charges on the outer
membrane can be reduced, leading to reduction in the affinity
of the positively charged polymyxin component, hence giving
rise to polymyxin resistance [10, 11, 15].
It is interesting that the 14 polymyxin-resistant isolates
displayed an identical P102Hmutation within the pmrA gene
and this mutation was identical to that previously reported
by Adams et al. (2009) [10] in a colistin-resistant deriva-
tive of A. baumannii AB0057. Overexpression of pmrAB
and mutations within these genes, especially pmrB, were
reported to contribute to polymyxin resistance [10, 11, 16].
As expression levels of pmrAB were not determined in this
study and no mutation within pmrB was found, we are not
certain if the P102H mutation in pmrA is a contributing
factor to the polymyxin resistance in the 14 XDR isolates.
However, analysis of the LPS biosynthesis genes identified
novel mutations especially in the lpxD, lpxC, and lpsB genes.
All 14 XDR isolates had mutations in both lpxD and lpxC
genes whereas 8 out of the 14 isolates showed an identical
H181Y substitution in lpsB. It does appear that disruption
in the LPS biosynthesis genes could be associated with
polymyxin resistance in the A. baumannii isolates studied.
The effects of these mutations on the LPS of these isolates
need to be further investigated as they differ from the
mutations previously reported [30]. Furthermore the crystal
structure of the A. baumannii LpxD protein was recently
elucidated [31] and one of the mutations (G186S) lies within
the proposed active site of the enzyme.Nevertheless, it should
be noted that in a recent study [14], screening of transposon
mutant libraries led to the identification of more than 20
genes that may be involved in inducible colistin resistance
in A. baumannii. Most of these genes converge on pathways
involved in osmotolerance, cell envelope biosynthesis along
with protein folding [14]. The role that these factors may play
in the development of polymyxin resistance among the 14
XDR isolates would also need to be investigated.
PFGE results indicated that the polymyxin-resistant iso-
lates were genetically diverse. This is in contrast to the
carbapenem-resistant isolates which were clonally related.
The carbapenem-resistant cluster A was the largest cluster
inferring that this is the major clonal group of A. bau-
mannii existing within the hospital in 2011. Four of the 21
isolates within the A cluster were polymyxin resistant and
XDR with three of these isolates having MIC values for
polymyxin B > 128 𝜇g/mL. Similar results were obtained
whereby polymyxin-resistant isolates were found in clusters
E, B, and C although the MIC values for these isolates were
≤ 32 𝜇g/mL. The clustering of carbapenem-resistant isolates
has indeed been previously reported [32, 33]. Carbapenem
resistance is due mainly to the acquisition of carbapenemases
such as OXA-23 which are encoded on plasmids and other
mobile elements. Isolates that acquire such genes will then
undergo clonal expansion [34, 35]. In contrast, polymyxin
resistance has been shown to develop through mutations in
certain determinants in response to selection pressure [10–13,
17].Thus these isolates were likely to develop randomly in the
presence of polymyxins. Since polymyxin resistance is due to
alterations or the complete absence of the outer membrane of
LPS, it may incur a fitness cost to the bacterium. Therefore
these isolates may not persist in the absence of polymyxin
which could explain the random, nonclustering nature of
the polymyxin-resistant isolates. This was indeed reported
in a recent paper [36] where colistin-susceptible isolates
outcompeted resistant isolates upon withdrawal of colistin
in three out of four cases. However, in one case, an isolate
with a pmrB L271R mutation appeared to be fit enough to be
transmitted in the absence of colistin and not be outcompeted
by susceptible isolates [36]. Colistin-resistant A. baumannii
has also been reported to have reduced virulence inmice [37]
although a more recent report indicated contrasting results
whereby colistin resistance may not necessarily intrinsically
affect virulence [38].
This is the first report of polymyxin-resistant and XDR
A. baumannii from Malaysia. The emergence of XDR and
polymyxin-resistant A. baumannii isolates from the main
tertiary hospital in Terengganu, Malaysia, is a cause of
concern. Stricter enforcement of antibiotic usage and an
antibiotic stewardship program are clearly needed in the
hospital to prevent the spread of XDR A. baumannii.
5. Conclusions
Multidrug resistant A. baumannii was observed in 39 of 54
isolates (72.2%) that were obtained from the main tertiary
hospital in Terengganu, Malaysia, throughout 2011. High
incidence of resistance to carbapenems (about 75%) was
noted. Of concern, 14 of the 54 isolates (25.9%) were char-
acterized as extensive drug resistant and were resistant to
polymyxin B, considered the drug of “last resort.” Pulsed-field
gel electrophoresis indicated that the polymyxin-resistant
isolates were genetically diverse. A P102H mutation was
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found in the pmrA gene in all polymyxin-resistant isolates.
In addition, novel mutations within the LPS biosynthesis
genes lpxC, lpxD, and lpsB were detected in the polymyxin-
resistant isolates. Whether these mutations contribute to
the development of polymyxin resistance in A. baumannii
requires further investigations.
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